Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 269

Combining FLASH and immunotherapy to target medulloblastoma relapse

Medulloblastoma (MB) is the most common childhood malignant brain tumor. Despite aggressive treatments such as surgical resection, radiotherapy and chemotherapy, the prognosis for many MB patients is grim: almost half of the patients die following tumor relapse. Thus, there is an urgent need for improved treatment of MB recurrence, which ...

Leveraging epigenetic alterations for therapy of diffuse midline glioma

Diffuse midline glioma (DMG) is a uniformly fatal brainstem tumor of childhood with no effective therapies. Given the failure of chemotherapy and radiation against DMG, we are pursuing strategies to enable effective immunotherapy for this disease. A major roadblock to immunotherapy is that DMG cells effectively ‘hide’ from ...

Cytokine signaling in diffuse midline glioma to enhance GD2-directed ...

Diffuse midline glioma (DMG) is a devastating brain and spinal cord tumor that occurs in children and is universally fatal, killing most patients within one year. New approaches using the body’s immune system to attack DMG have started to show promise for patients. Chimeric antigen receptor or “...

Radiation resistance in medulloblastoma

Medulloblastomas are childhood brain tumors occurring in the cerebellum, a region of the brain that regulates posture, coordination, and may play roles in cognition and emotion.  An important phase of cerebellar development takes place after birth, marked by very rapid division of cells destined to become cerebellar neurons.&...

Inducing iron overload by targeting iron-sulfur transport can activate ferroptosis ...

Abstract Medulloblastomas (MB) are amongst the most common and deadliest brain tumors of childhood. They are divided into four groups; group 3 (G3MB) patients have the lowest survival. Presently, all patients receive the same therapies, starting with surgical resection, followed by radiation and chemotherapy. G3MBs do not respond well ...

Targeting FOXR2 in diffuse midline gliomas

Diffuse midline glioma (DMG) is a deadly pediatric brain cancer. Despite radiation treatment, nearly all children diagnosed with the disease succumb to it with a median survival of 12 months. There have been few advancements in treatment, and current treatment has no curative intent. Therefore, there is a significant need to ...